BioNTech SE - ADR vs Anheuser-Busch Inbev SA — how do they compare? BioNTech SE - ADR trades at $92.8 (market cap $23.31B), while Anheuser-Busch Inbev SA trades at $79.59 (market cap $159.01B). The key difference: Anheuser-Busch Inbev SA is far larger — about 6.8× BioNTech SE - ADR's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | BUD | |
|---|---|---|
Market Cap | $23.31B | $159.01B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $86.48 |
52-Week Low | $83.89 | $57.93 |
Enterprise Value | $6.60B | $223.42B |
Dividend Yield | — | 1.67% |
Trailing returns across standard periods
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →